The Contribution of the Descending Pain Modulatory Pathway in Opioid Tolerance

Lindsay M. Lueptow, Amanda K. Fakira and Erin N. Bobeck

1 Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior UCLA, Los Angeles, CA, United States;
2 Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States;
3 Department of Biology, Utah State University, Logan, UT, United States

Opioids remain among the most effective pain-relieving therapeutics. However, their long-term use is limited due to the development of tolerance and potential for addiction. For many years, researchers have explored the underlying mechanisms that lead to this decreased effectiveness of opioids after repeated use, and numerous theories have been proposed to explain these changes. The most widely studied theories involve alterations in receptor trafficking and intracellular signaling. Other possible mechanisms include the recruitment of new structural neuronal and microglia networks. While many of these theories have been developed using molecular and cellular techniques, more recent behavioral data also supports these findings. In this review, we focus on the mechanisms that underlie tolerance within the descending pain modulatory pathway, including alterations in intracellular signaling, neural-glial interactions, and neurotransmission following opioid exposure. Developing a better understanding of the relationship between these various mechanisms, within different parts of this pathway, is vital for the identification of more efficacious, novel therapeutics to treat chronic pain.

Keywords: opioid, tolerance, periaqueductal gray (PAG), RVM, dorsal horn

DESCENDING PAIN PATHWAY IN OPIOID FUNCTIONS

Opioids are widely used pain therapeutics; however, the development of tolerance limits the long-term use of opioids due to the need for dose escalation over time in order to maintain analgesia. While there are four main types of opioid receptors, most pain therapeutics, including morphine, methadone, fentanyl, and oxycodone, target the mu opioid receptor (MOPr). The MOPr is a G-protein coupled receptor that couples to inhibitory heterotrimeric G-proteins (G\textsubscript{i/o}) producing subsequent intracellular signaling and ion conductance (Goode and Raffa, 1997; Gintzler and Chakrabarti, 2004). MOPr expression within the descending pain modulatory pathway, which includes the ventrolateral periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and the dorsal horn (DH) of the spinal cord, contribute to opioid-induced antinociception and the development of opioid tolerance (Fang et al., 1989; Fairbanks and Wilcox, 1997; Tortorici et al., 2001; Morgan et al., 2006; Bobeck et al., 2009).

GABAergic neurons within the PAG are a critical site of action by opioids. Under normal conditions, these neurons have tonic activity (Figure 1, naive); however, upon binding of opioids to MOPr, the activity of these neurons is decreased, disinhibiting PAG projections to the RVM (Figure 1, Acute Morphine) (Stiller et al., 1996; Vaughan et al., 1997; Bobeck et al., 2014). In vitro
Electrophysiology studies have shown that opioids reduce the frequency of spontaneous mIPSCs in PAG (Vaughan et al., 1997; Bobeck et al., 2014), which indicates a reduction in the probability of GABA release. This is also supported by in vivo studies. Microinjection of bicuculline (GABA_A agonist) into the PAG produces antinociception, which suggests that GABA is being tonically released (Bobeck et al., 2014). Furthermore, microdialysis in the PAG reveals a reduction in extracellular GABA following administration of morphine (Stiller et al., 1996).

Opioids activate different signaling cascades depending on whether the MOPr is expressed at pre- or post-synaptic sites. Opioid binding to postsynaptic MOPr results in the activation of a G-protein inwardly-rectifying potassium channels (GIRK) that hyperpolarize GABAergic neurons in the PAG producing an overall decrease in GABAergic neuron activity (Figure 1; Acute Morphine) (North and Williams, 1983; Pan et al., 1990). Alternatively, when MOPr are expressed at presynaptic sites they produce an inhibition of voltage gated calcium channels and voltage gated potassium channels (Kv) resulting in the inhibition of GABA release (Figure 1; Acute Morphine) (Wilding et al., 1995; Vaughan et al., 1997; Connor et al., 1999; Williams et al., 2001). Overall, the combined action of MOPr binding by opioids is a decrease in GABAergic neuronal activity, and therefore an increase in output from the PAG to the RVM (Figure 1; Moreau and Fields, 1986; Depaulis et al., 1987; Jacquet, 1988; Osborne et al., 1996). Recent studies support the hypothesis that this increase in PAG output to the RVM is a main contributor to the opioid-induced antinociception by demonstrating that selective inhibition of GABAergic neurons or activation of glutamatergic output neurons in the PAG mimics the antinociceptive effects of opioids (Samineni et al., 2017). In summary, these findings support the notion that analgesia is produced by disinhibition of excitatory outputs from the PAG.

The overall effect of MOPr activation in the PAG is an increase in output to the two distinct cell types within the RVM: off-cells and on-cells (Fields et al., 1983; Fields and Heinricher, 1985). The activity of off-cells pauses just prior to the response to a painful stimulus, while the activity of on-cells increases during this response, and both of these activities are blocked during the administration of opioids. There is conflicting evidence regarding the excitatory versus inhibitory nature of the PAG projections to the on- and off-cells in the RVM. Studies in GAD67-GFP mice, a marker for GABAergic neurons, show that retrogradely labeled neurons from the RVM do no colocalize with GAD67 in the PAG (Park et al., 2010), indicating that the PAG to RVM projection is glutamatergic. In contrast, studies in rats demonstrate that PAG to RVM projections are a mix of GABAergic and glutamatergic neurons (Morgan et al., 2008). Furthermore, these studies demonstrate that GABAergic neurons project from PAG and target on-cells and glutamatergic neurons project from the PAG and target off-cells (Morgan et al., 2008). Despite these differences, both studies support the notion that opioids inhibit GABA release from interneurons in the PAG, which disinhibits (i.e., excite) glutamate projections to off-cells. Given that the off-cells in the RVM are GABAergic, they subsequently inhibit pain responses in the DH (Fields et al., 1983; Moreau and Fields, 1986; Morgan et al., 2008). Overall, these studies support the concept that opioid-induced antinociception is mediated by direct excitation of off-cells and subsequent inhibition of pain in the spinal cord.

At each level of this pathway, a myriad of cellular effects drives the physiological changes mentioned above, and are highly correlated with the development of opioid tolerance. One of the most studied mechanisms involves regulation and signaling at the MOPr. Current research demonstrates that while MOPr is a key player in the development of antinociceptive tolerance, mechanisms beyond simple receptor desensitization, including alterations in neurotransmission and β-arrestin dependent signaling, are also critical. Furthermore, MOPr expression in non-neuronal cells, specifically on microglia and astrocytes within the spinal cord, and more recently within the PAG, greatly contributes to the development of opioid tolerance.

**OPIOID TOLERANCE AND NEUROTRANSMISSION IN THE DESCENDING PAIN PATHWAY**

Evidence suggests that tolerance is due to changes in the properties of GABAergic neurons in the PAG (Morgan et al., 2003). First of all, while microinjection of morphine into the PAG or RVM produces antinociception, repeated microinjection into the PAG and not the RVM results in tolerance (Morgan et al., 2005; Campion et al., 2016). Secondly, inhibition of MOPrs within the PAG blocks tolerance to systemic morphine (Lane et al., 2005). Furthermore, inactivation of RVM by a GABA agonist during direct administration of morphine into the PAG still leads to tolerance development (Lane et al., 2005). Therefore, MOPr within the PAG are necessary and sufficient in the development of opioid tolerance.

However, the development of tolerance within the PAG produces downstream effects along the descending pain pathway. This is evidenced by the fact that direct injection of morphine into the PAG affects RVM signaling, suggesting that their activity is in fact coupled (Tortoricci et al., 2001). While acute administration of opioids into the PAG disrupts the activity of on- and off-cells in response to painful stimuli, these cells respond normally following chronic infusion that is associated with tolerance (Lane et al., 2004). Another side effect of chronic morphine treatment is hyperalgesia, or the increased sensitivity to pain following chronic morphine treatment. One theory is that hyperalgesia may manifest as opioid-induced tolerance since increased sensitivity to pain would counteract the pain-relieving effects of opioids. Some studies suggest that increased activation of the descending pain pathway by chronic morphine produces neuroadaptations with in the RVM that result in hyperalgesia (Vanderah et al., 2001). In support of this, one study demonstrated that chronic morphine produced an increase in the number of active on-cells, likely increasing sensitivity to noxious stimuli (Meng and Harasawa, 2007), which may be responsible for morphine-induced hyperalgesia. While RVM plays a role in opioid-induced tolerance, direct injections into the RVM leads to a lesser development of tolerance compared to PAG administration.
FIGURE 1 | The effects of morphine on neuronal transmission in the descending pain pathway. In the naïve state, GABAergic interneurons in the periaqueductal gray (PAG) fire tonically, thereby producing a steady release of GABA and inhibition of PAG output neurons. Upon administration of acute morphine, postsynaptic mu opioid receptor (MOPr) activate GIRK channels via Gα proteins resulting in K+ release and hyperpolarization of the neuron. Additionally, MOPr activate Gι/ο proteins, which result in the inhibition of adenylyl cyclase (AC) and decrease cAMP production. Morphine binding of presynaptic MOPr inhibits voltage dependent calcium (Ca2+) conductances via Gβγ proteins and activated voltage dependent potassium conductances (Kv) via Phospholipase A (PLA). Overall, these two mechanisms block release of the neurotransmitter GABA, therefore suppressing inhibition, increasing output, of the PAG neurons projecting to the rostral ventromedial medulla (RVM). Acute morphine treatment also activates toll-like receptor 4 (TLR4) receptors on astrocytes and microglia in the PAG inducing several signaling cascades. (Morgan et al., 2005), indicating that activation of the entire descending pain circuit is essential.

The neurophysiological mechanisms of tolerance in the PAG are mediated by MOPr uncoupling from downstream G-protein mediated signaling (Figure 2). One key study demonstrated that chronic morphine decreases opioid-mediated GIRK currents in the PAG (Bagley et al., 2005), supporting the notion that morphine tolerance is associated with uncoupling of G-protein mediated signaling. Since GIRK channels regulate neuronal excitability, this mechanism would result in a reduction in the ability of MOPr activation to suppress GABAergic neuron activity. Additionally, morphine tolerance is also associated with decreased efficacy of other MOPr agonists ability to reduce voltage gated calcium currents in the PAG (Bagley et al., 2005). The net effect of the uncoupling of MOPr activation from voltage gated calcium channels would be the attenuation of MOPr mediated inhibition of GABA release. However, the precise mechanisms underlying MOPr uncoupling from voltage gated calcium channels are complex, as cellular tolerance associated with this effect was not observed in β-arrestin two knockout mice (Connor et al., 2015), suggesting that β-arrestin two also plays a role in this interaction.

GABA release is also regulated by signaling through phospholipase A2-mediated activation of voltage gated potassium channels (Figure 1; Wimpey and Chavkin, 1991; Vaughan et al., 1997). This signaling pathway is differentially affected by morphine tolerance versus withdrawal. Morphine tolerance is associated with a decrease in opioid-mediated inhibition of GABA release (Figure 2) that is not a result of MOPr desensitization (Fyfe et al., 2010). However, during naloxone-precipitated withdrawal following chronic morphine, GABA release is enhanced via an increase in adenylyl cyclase (AC) signaling (Sharma et al., 1975; Ingram et al., 1998; Hack et al., 2003). These two outcomes may be related as studies have
Intracellular Signaling Changes in the PAG-RVM-DH Pathway in Opioid Tolerance

Direct activation of the MOPr results in the Gα subunit-mediated inhibition of the AC-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway (Figure 1; Sharma et al., 1975; Guitart and Nestler, 1989; Hirst and Lambert, 1995). However, opioid binding activates other signaling proteins, such as protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) via β-arrestin pathways, which are independent of G-protein signaling. As mentioned previously, downstream of G-protein-mediated signaling, there is an inhibition of calcium channels and activation of potassium channels that leads to hyperpolarization and a reduction in neurotransmitter release in the PAG that produces antinociception (Bourinet et al., 1996; Ippolito et al., 2002; Torrecilla et al., 2002). Chronic morphine produces adaptations that contribute to opioid-tolerance within all these downstream signaling pathways.

Long-term opioid treatment leads to adaptations in many signaling proteins within the PAG-RVM-DH pathway, which have been proposed as mechanisms of opioid tolerance. In contrast to the acute inhibitory effect of opioids on cAMP production, chronic morphine treatment upregulates cAMP (Figure 2; Guitart and Nestler, 1989; Gintzler and Chakrabarti, 2004). It has been proposed that this upregulation in cAMP is caused by compensatory changes in intracellular signaling, or an uncoupling of Gi/o-proteins from the receptor and a switch to coupling with Gs-proteins (Gintzler and Chakrabarti, 2004). Very few in vivo studies have evaluated the role of the AC pathway in morphine tolerance, but inhibition of the AC pathway, via either intracerebroventricular (ICV) or intra-PAG injection, during morphine pretreatment has been shown to block the development of morphine tolerance (Smith et al., 2006; Gabra et al., 2008; Bobeck et al., 2014). In the DH, administration of morphine results in no change or even an increase in MOPr expression, but a significant down-regulation of the G-protein activation in the DH, as measured by [35S]-GTPyS (Maher et al., 2001; Ray et al., 2004). The loss of G-protein signaling is likely a switch in MOPr G-protein coupling, from Gi/o to Gs coupling (Gintzler and Chakrabarti, 2004). Recently, adrenomedullin, a pronociceptive peptide from the CGRP family, has been implicated in mediating this G-protein switch in the DH. Following chronic morphine, adrenomedullin is significantly upregulated in the DH and dorsal root ganglia, and inhibition of its receptor prevents or reverses morphine tolerance and blocks the MOPr Gi/o to Gs switch in coupling (Wang et al., 2016).

Behavioral studies suggest that the mechanisms underlying tolerance are dependent on the specific MOPr agonist being studied. Some agonists, such as morphine, do not readily recruit β-arrestin or internalize the receptor, as compared to high efficacy agonists, such as DAMGO or fentanyl, which readily do both. This difference in signaling suggests differences in tolerance mechanisms, where morphine-mediated tolerance utilizes a G-protein dependent mechanism, and other MOPr agonists, such as DAMGO or fentanyl, use a β-arrestin dependent mechanism (Hull et al., 2010; Melief et al., 2010; Bobeck et al., 2014, 2016; Morgan et al., 2014). For example, inhibition of ERK1/2 within the PAG during the development of tolerance enhances morphine tolerance (Macey et al., 2009), but reduces tolerance to DAMGO and has no effect on fentanyl tolerance (Bobeck et al., 2016). Furthermore, inhibition of the G-protein dependent pathway (i.e., c-Jun N-terminal kinase) blocks development of tolerance to morphine, but not fentanyl. However, inhibition of β-arrestin dependent signaling (i.e., G protein-coupled receptor kinase) blocks expression of fentanyl tolerance (Morgan et al., 2014).

Neuropeptides within the descending pain pathway have also been shown to regulate opioid tolerance. One such neuropeptide, cholecystokinin (CCK), is particularly enriched in supraspinal midbrain regions known to regulate spinal...
nociception (King et al., 2005). There is evidence that CCK acting within the PAG-RVM-DH pathway regulates morphine tolerance (Xie et al., 2005; Thomas et al., 2015). A CCK receptor antagonist, directly injected into the PAG, is able to block morphine tolerance (Xie et al., 2005). In the RVM, injection of CCK blocks opioid activation of off-cells that mediate descending antinociception, resulting in a blockade of the analgesic effects of morphine (Xu et al., 2014; Thomas et al., 2015).

N-methyl D-aspartate receptors (NMDArs) have been heavily implicated in the development of both spinal-mediated hyperalgesia and opioid tolerance. NMDAr antagonists or the targeted disruption of the NR2 subunits, NR2a and NR2b, attenuates opioid tolerance (Price et al., 2000; Zhao et al., 2012). Deletion of PSD-93, the anchoring protein for NR2a and NR2b in the synapse, leads to a DH site-specific down-regulation of both subunits from the plasma membrane into the cytosolic compartment, and a reduction in the development of morphine tolerance (Liaw et al., 2008). This is a region-specific effect, as other portions of the descending pain pathway did not see changes in the NR2 subunit localization (Kozela and Popik, 2007). Interestingly, NMDArs in the PAG have not been implicated in tolerance (Morgan et al., 2009).

A few other main signaling targets have been implicated in DH-mediated opioid tolerance, as well. Mammalian target of rapamycin (mTOR) is found to be upregulated following repeated intrathecal morphine administration, and this effect is mediated by activation of PI3K/AKT following MOPr activation (Xu et al., 2015). Administration of mTOR inhibitors is able to both prevent and reverse morphine tolerance (Xu et al., 2014, 2015; Jiang et al., 2016; Chen et al., 2017). Calcium/calmodulin-dependent protein kinase IIa has also been implicated in the development of tolerance (Brüggemann et al., 2000). It has been shown to colocalize with MOPr in the DH specifically, following opioid administration, possibly resulting in increased MOPr phosphorylation and desensitization (Brüggemann et al., 2000).

One prominent pro-inflammatory signaling cascade that has been implicated in opioid tolerance involves the immune receptor, toll-like receptor 4 (TLR4, Figure 2). Upon agonist binding to TLR4, spongomyelinase produces ceramide, which allows for interaction of the receptor with its co-activators myeloid differentiation factor-2 (MD-2) and CD14, resulting in subsequent activation of 3 parallel pathways: the p38-MAPK pathway, the PI3K/AKT pathway (cell survival/apoptosis), and the NfkB pathway (proinflammatory cytokine release) (Rönnbäck and Hansson, 1988; Watkins et al., 2009; Nakamoto et al., 2012; Eidson and Murphy, 2013). In the spinal cord, TLR4 is primarily expressed on microglial cells and is shown to be upregulated (Figure 2) along with its cofactor MD-2 following morphine treatment (Wang et al., 2012), and activation of TLR4 signaling can induce “naive tolerance” to opioids (Eidson and Murphy, 2013; Grace et al., 2015). Furthermore, inhibition of TLR4, co-activators MD-2 or CD14, or inhibition of ceramide biosynthesis, leads to attenuation of morphine tolerance, as well as decreased microglial activation, suggesting a prominent role for the TLR4 pathway in the development of opioid tolerance, at the level of the spinal cord (Ndengele et al., 2009; Hutchinson et al., 2010, 2011; Muscoli et al., 2010; Thomas et al., 2015).

Interestingly, it is also thought that TLR4 is directly activated by opioids (Figures 1, 2; Hutchinson et al., 2011; Wang et al., 2012; Grace et al., 2015), and, perhaps more importantly, the accessory protein MD-2 is able to non-stereoselectively bind opioids and signal through TLR4 (Grace et al., 2015). Since the classic opioid receptors only bind the (-)-opioid isomer, the (+)-opioid isomer antagonists could be used to block TLR4-mediated microglial activation and pro-inflammatory cytokine production. In fact, studies have demonstrated that (+)-naloxone is able to attenuate morphine-induced analgesia, specifically at the level of the spinal cord (Hutchinson et al., 2010; Lewis et al., 2010). This non-stereoselectivity at the TLR4 receptor complex could potentially be leveraged for the enhancement of the therapeutic efficacy of opioids, including enhancing analgesic effects and reducing tolerance.

How does the activation of glial cells lead to alterations in neuronal signaling? One possibility is through the alteration of neuronal excitability via increased release of glially-derived pro-inflammatory cytokines, including TNF (tumor necrosis factor) and IL-1β, which are known to increase neuronal AMPA and NMDA receptors, as well as down regulate GABA receptors (Viviani et al., 2003; Stellwagen, 2005). Within the PAG, repeated morphine administration results in an upregulation of TLR4, which subsequently leads to an increase in release of TNF and IL-1β (Eidson and Murphy, 2013; Eidson et al., 2017). This upregulation is concurrent with a downregulation of astrocyte glutamate transporters GLT-1 and GLAST, which are responsible for synaptic glutamate uptake. The overall effect is an increase in neuronal excitability, thereby lowering the ability of opioids to hyperpolarize mu-containing GABAergic neurons (Figure 2). Within the PAG to RVM circuitry, this results in an inability for morphine to disinhibit output neurons to RVM (Eidson and Murphy, 2013; Eidson et al., 2017).

Another potential point of cross talk is via purinergic receptors, specifically P2X4 and P2X7, which are primarily

IMPACT OF OPIOID-INDUCED NEUROINFLAMMATION ON THE DEVELOPMENT OF TOLERANCE

Over the past few decades, researchers have discovered that opioids are potent activators of immune cells within the CNS, and this inflammation is a strong contributor to the development of opioid tolerance (Giron et al., 2015; Cahill and Taylor, 2017). Specifically, repeated administration of opioids, which leads to activation of glia within the PAG and spinal cord of the descending pain pathway, results in alterations in both intracellular signaling cascades and signaling properties of neurons. Furthermore, microglial inhibitors have been shown to attenuate morphine-induced tolerance (Song and Zhao, 2001; Raghavendra et al., 2002, 2004; Cui et al., 2008; Eidson and Murphy, 2013; Harada et al., 2013). Though the precise mechanisms that underlie these changes are only beginning to be uncovered, a few notable pathways have emerged that are likely significant contributors to the development of opioid tolerance.
expressed on microglia. These receptors are also capable of upregulating pro-inflammatory cytokines, and blocking their activity in the spinal cord attenuates morphine tolerance (Horvath et al., 2010; Zhou et al., 2010; Xiao et al., 2015). P2X4 activates the p38-MAPK pathway, resulting in the release of IL-1β, TNF-α, and BDNF, which, as mentioned above, are known to alter neuronal excitability and contribute to pain hypersensitivity, but no direct connection has been made to opioid tolerance (Ferrini et al., 2013; Grace et al., 2015; Thomas et al., 2015). However, P2X7 mediated release of IL-18 from microglia induces activation of the IL-18 receptor on astrocytes, thereby increasing the release of D-serine, which is able to activate NMDA receptors in neurons. Activation of both receptors is able to alter glial activation and neuronal excitability, suggesting a complicated crosstalk between cell types in the spinal cord that is correlated with morphine tolerance (Chen et al., 2012).

CONCLUSION

The descending pain pathway is a critical modulator of nociception and plays an important role in mediating endogenous and exogenous opioid-induced analgesia. Because of this, it is highly implicated in allostatic cellular and molecular changes following repeated opioid use that lead to the development of tolerance. While this review has touched on a number of those changes at each level of the descending pain pathway, including desensitization of MOPr, altered cellular excitability and signaling, and induction of immune-competent cells, we do not yet have a complete understanding of all the factors that might be contributing to opioid tolerance.

Much of the literature on opioid tolerance has focused the effects of morphine on this system. Future research must expand to include other commonly used opioids, especially in light of the increasing use of oxycodone and fentanyl, as each of these potent opioids, tolerance, and activation of neurons from PAG to RVM following morphine, as compared to females (Loyd et al., 2008), it is imperative to further explore these differences. Overall, these variations in research design have resulted in a myriad of observed cellular changes that correlate with tolerance, but with no definite conclusions or unifying theories of tolerance. While no one specific etiology may exist, future researchers must be careful in designing these studies, in order to make meaningful conclusions regarding the cellular impact of opioids in the development of tolerance.

AUTHOR CONTRIBUTIONS

LL, AF, and EB contributed to the writing and editing of this manuscript.

FUNDING

This work was supported by a Young Investigator Grant from the Brain and Behavior Research Foundation to EB, National Institute Health Award T32 DA007135 to LL.

REFERENCES


Connor, M., Schuller, A., Pintar, J. E., and Christie, M. J. (1999). µ-opioid receptor modulation of calcium channel current in periaqueductal grey neurons from the brain and behavior research foundation to eb, national institute health award t32 da007135 to ll.
Nakamoto, K., Kawasaki, S., Kobori, T., Fujita-Hamabe, W., Mizoguchi, H.,
Ndengele, M. M., Cuzzocrea, S., Masini, E., Vinci, M. C., Esposito, E., Muscoli, C.,
Frontiers in Neuroscience | www.frontiersin.org
November 2018 | Volume 12 | Article 886

doi: 10.1007/BF02702561
Sammineni, V. K., Grajales-Reyes, J. G., Copits, B. A., O’Brien, D. E., Trigg,
glutamatergic and gabaergic neuronal subpopulations in the periaqueductal
72, 3092–3096. doi: 10.1073/pnas.72.8.3092
PKC and PKA inhibitors restate morphine-induced behaviors in morphine
Song, P., and Zhao, Z.-Q. (2001). The involvement of glial cells in the development
00226–1
doi: 10.1523/JNEUROSCIENCE.4886-04.2005
administration of morphine decreases the extracellular level of GABA in the
doi: 10.1016/0304-3940(96)01268-0
relationship between opioids and immune signaling in the spinal cord. Handb.
Torrecilla, M., Marker, C. L., Cintora, S. C., Stoffel, M., Williams, J. T., and
Wickman, K. (2002). G-protein-gated potassium channels containing Kir3.2 and
Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus
ceruleus neurons. J. Neurosci. 22, 4328–4334. doi: 10.1523/JNEUROSCIENCE.22-11-
04328.2002
microinjection of morphine into the periaqueductal gray is associated with
changes in the behavior of off- and on-cells in the rostral ventromedial
JNEUROSCIENCE.23-25-08692.2003
Contribution of adrenomedullin to the switch of G protein-coupled
receptors from Gi to Gs in the spinal dorsal horn following chronic
pharm.1200130109
Vanderah, T. W., Suenaga, N. M., Ossipov, M. H., Malan, T. P., Lai, J., and
Porreca, F. (2001). Tonic descending facilitation from the rostral ventromedial
dentia mediate opioid-induced abnormal pain and antinociceptive tolerance. J.
doi: 10.1038/37610
Viviani, B., Bartsaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T.,
et al. (2003). Interleukin-1β enhances NMDA receptor-mediated intracellular
calcium increase through activation of the Src family of kinases. J. Neurosci. 23,
Contribution of adrenomedullin to the switch of G protein-coupled µ-opioid
receptors from Gi to Gs in the spinal dorsal horn following chronic
13419
Wang, X., Loram, L. C., Ramos, K., de Jesus, A. J., Thomas, J., Cheng, K.,
et al. (2012). Morphine activates neuroinflammation in a manner parallel to
1200130109
of opioid-induced glial activation: improving the clinical efficacy of opioids by
002
signal transduction between the mu opioid receptor and Ca2+ channels. J.
1241985
1152/physrev.2001.81.1.299


**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.